NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

Last Close
Jun 30 04:00PM ET
1.10
Dollar change
0.00
Percentage change
0.00
%
IndexRUT P/E- EPS (ttm)-1.58 Insider Own28.94% Shs Outstand61.63M Perf Week-9.09%
Market Cap68.14M Forward P/E- EPS next Y-1.20 Insider Trans0.00% Shs Float44.02M Perf Month-12.00%
Enterprise Value-18.92M PEG- EPS next Q-0.35 Inst Own37.56% Short Float14.04% Perf Quarter3.77%
Income-95.23M P/S- EPS this Y-4.29% Inst Trans-4.54% Short Ratio10.92 Perf Half Y-31.25%
Sales0.00M P/B0.66 EPS next Y13.20% ROA-53.49% Short Interest6.18M Perf YTD-29.49%
Book/sh1.67 P/C0.64 EPS next 5Y2.24% ROE-66.30% 52W High5.39 -79.59% Perf Year-65.73%
Cash/sh1.73 P/FCF- EPS past 3/5Y17.52% -74.92% ROIC-78.42% 52W Low0.83 32.02% Perf 3Y-56.00%
Dividend Est.- EV/EBITDA- Sales past 3/5Y- - Gross Margin- Volatility7.93% 6.72% Perf 5Y-
Dividend TTM- EV/Sales- EPS Y/Y TTM-14.09% Oper. Margin- ATR (14)0.08 Perf 10Y-
Dividend Ex-Date- Quick Ratio7.75 Sales Y/Y TTM-100.00% Profit Margin- RSI (14)41.23 Recom1.33
Dividend Gr. 3/5Y- - Current Ratio7.75 EPS Q/Q-445.83% SMA20-10.79% Beta1.14 Target Price6.20
Payout- Debt/Eq0.19 Sales Q/Q-100.00% SMA50-6.16% Rel Volume0.64 Prev Close1.10
Employees44 LT Debt/Eq0.18 EarningsMay 15 BMO SMA200-42.93% Avg Volume566.18K Price1.10
IPOOct 08, 2021 Option/ShortYes / Yes EPS/Sales Surpr.-19.05% - Trades Volume361,623 Change0.00%
Date Action Analyst Rating Change Price Target Change
Nov-21-24Downgrade William Blair Outperform → Mkt Perform
Nov-08-24Initiated Stephens Overweight $13
Aug-08-24Initiated Stifel Buy $10
May-07-24Resumed Jefferies Buy $10
Feb-09-24Initiated BTIG Research Buy $8
Jan-23-24Initiated Leerink Partners Outperform $12
Sep-05-23Initiated RBC Capital Mkts Outperform $7
Nov-02-21Initiated Jefferies Buy $25
Nov-02-21Initiated Credit Suisse Outperform $19
Nov-02-21Initiated BofA Securities Neutral $16
Jun-30-25 04:30PM
May-15-25 07:00AM
May-14-25 07:30AM
Apr-25-25 01:17PM
Apr-24-25 08:56AM
09:32AM Loading…
Apr-23-25 09:32AM
Apr-16-25 09:45AM
Apr-02-25 07:30AM
Mar-25-25 04:30PM
Mar-18-25 07:30AM
Mar-03-25 07:30AM
Feb-26-25 07:30AM
Feb-04-25 07:30AM
Dec-21-24 07:40AM
Dec-19-24 04:08PM
04:05PM Loading…
Nov-20-24 04:05PM
Nov-12-24 07:30AM
Nov-11-24 07:00AM
Aug-29-24 07:30AM
Aug-14-24 04:05PM
Jul-29-24 08:00AM
Jun-28-24 04:30PM
Jun-10-24 07:30AM
May-30-24 07:30AM
May-14-24 03:53PM
08:40AM
07:30AM
May-09-24 07:30AM
Apr-12-24 09:55AM
Mar-28-24 04:30PM
07:30AM Loading…
Mar-27-24 07:30AM
Mar-26-24 12:00PM
Mar-21-24 01:53PM
09:11AM
07:30AM
Mar-13-24 08:00AM
Mar-07-24 04:30PM
Mar-05-24 04:45PM
Feb-27-24 08:00AM
Dec-29-23 04:30PM
Nov-28-23 07:00AM
Nov-07-23 04:30PM
Oct-23-23 11:27AM
Oct-13-23 09:00AM
Sep-27-23 09:18AM
Sep-14-23 05:03PM
Aug-31-23 04:01PM
Aug-23-23 08:35AM
Aug-11-23 07:00AM
Aug-01-23 04:01PM
Jun-30-23 05:00PM
May-30-23 08:30AM
May-24-23 06:45AM
May-11-23 07:00AM
Mar-31-23 05:00PM
Mar-30-23 02:16PM
Mar-22-23 06:45AM
Mar-16-23 07:30AM
Feb-13-23 08:00AM
Dec-23-22 04:45PM
Dec-01-22 06:45AM
Nov-01-22 06:30AM
Sep-30-22 05:00PM
Aug-15-22 07:00AM
Jul-12-22 06:45AM
Jun-28-22 06:35AM
Jun-21-22 10:40AM
May-19-22 06:35AM
May-13-22 08:03AM
May-07-22 10:34AM
Apr-27-22 06:35AM
Apr-13-22 06:35AM
Apr-08-22 01:05PM
Mar-29-22 11:00AM
06:35AM
Mar-22-22 06:35AM
Jan-10-22 11:17AM
Dec-15-21 08:00AM
Dec-09-21 08:30AM
Nov-15-21 07:15AM
Nov-10-21 08:00AM
Oct-08-21 03:31PM
Oct-07-21 10:24PM
Pyxis Oncology, Inc. engages in the business of developing a multi-modality portfolio of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. The firm focuses on the development of product candidates to directly kill tumor cells and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion. The company was founded by David Steinberg, Shaan C. Gandhi, and John L. Flavin on June 11, 2018 and is headquartered in Boston, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
HUMPHREY RACHELDirectorApr 21 '25Proposed Sale1.0313,89614,362Apr 21 04:14 PM
HUMPHREY RACHELDirectorApr 17 '25Proposed Sale0.97200194Apr 17 04:27 PM
HUMPHREY RACHELDirectorApr 14 '25Proposed Sale0.971,4001,362Apr 14 04:05 PM
Connealy Pamela AnnCFO & COONov 26 '24Buy1.9688,850174,3641,199,143Nov 27 05:09 PM